Annual Uterine Cancer Symposium

年度子宫癌研讨会

基本信息

批准号：
7285647
负责人：
Karen Hsieh Lu
金额：
$ 0.6万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
起止时间：
2004-09-01 至 2009-08-31
项目状态：
已结题

项目摘要

DESCRIPTION (provided by applicant): Endometrial cancer is the most common gynecologic malignancy in the United States. Funding for endometrial cancer has traditionally lagged behind that for other gynecological tumors, such as cervical cancer and ovarian cancer. Consequently, in the past there has been a lack of a coordinated basic and translational research effort devoted to endometrial cancer. In 2003, a group of basic scientists and physician scientists from M.D. Anderson Cancer Center applied for and received NCI funding for an Endometrial Cancer SPORE. This group of investigators currently represents the only concentrated group of federally funded endometrial cancer researchers in the United States. For innovative, translational research in endometrial cancer to move forward, it will be necessary to bring together clinical investigators and laboratory scientists from a variety of different institutions across the country. Therefore, we propose to organize an annual Uterine Cancer Symposium with the following goals: 1) provide a meaningful forum to discuss cutting-edge developments in endometrial cancer biology; 2) attract experts in related fields (such as breast cancer and endocrinology) to encourage multi-disciplinary interactions; 3) promote collaborations between basic scientists and clinical investigators for the development of more innovative, high-impact translational research in endometrial cancer; and 4) encourage young, talented post-doctoral fellows, clinical residents/fellows, and faculty at the assistant professor level to enter the field of endometrial cancer research. The proposed Endometrial Cancer Symposium will be held on an annual basis in Houston, Texas. We successfully organized the 1st Uterine Cancer Biology Symposium in Houston in 2002, and we have a program of confirmed speakers for the 2nd Symposium to be held September 27 and 28, 2004. Topics for the annual Uterine Cancer Symposium series include hormonal mechanisms in endometrial cancer, molecular differences between aggressive (Type 2) and non-aggressive (Type 1) endometrial cancer, epidemiology of endometrial cancer, chemoprevention in high risk cohorts, endometrial hyperplasia/biomarkers of risk, mouse and cell culture models of endometrial cancer, and genetic events important in normal uterine development. For each symposium, a mixture of clinical topics and basic science topics will be presented to promote the development of quality translational research.

描述（由申请人提供）：子宫内膜癌是美国最常见的妇科恶性肿瘤。传统上，用于子宫内膜癌的资金落后于其他妇科肿瘤，例如宫颈癌和卵巢癌。因此，过去缺乏致力于子宫内膜癌的协调基础和转化研究工作。 2003年，医学博士安德森癌症中心的一群基础科学家和医师科学家申请并获得了子宫内膜癌孢子的NCI资金。目前，这组研究人员代表了美国唯一集中的联邦基金癌症研究人员。为了使子宫内膜癌的创新，转化研究继续前进，有必要将来自全国各种不同机构的临床研究人员和实验室科学家汇集在一起。因此，我们建议组织一年的子宫癌研讨会，其目标：1）提供一个有意义的论坛，讨论子宫内膜癌生物学的最先进发展； 2）吸引相关领域的专家（例如乳腺癌和内分泌学）来鼓励多学科的相互作用； 3）促进基础科学家与临床研究者之间的合作，以开发子宫内膜癌的更具创新性，高影响力的转化研究； 4）鼓励年轻，才华横溢的博士后研究员，临床居民/研究员和助理教授级别的教职员工进入子宫内膜癌症研究领域。拟议的子宫内膜癌研讨会将每年在德克萨斯州休斯敦举行。 We successfully organized the 1st Uterine Cancer Biology Symposium in Houston in 2002, and we have a program of confirmed speakers for the 2nd Symposium to be held September 27 and 28, 2004. Topics for the annual Uterine Cancer Symposium series include hormonal mechanisms in endometrial cancer, molecular differences between aggressive (Type 2) and non-aggressive (Type 1) endometrial cancer, epidemiology of子宫内膜癌，高风险队列中的化学预防，子宫内膜癌风险的子宫内膜增生/生物标志物，子宫内膜癌的小鼠和细胞培养模型以及对正常子宫发育重要的遗传事件。对于每个研讨会，将介绍临床主题和基础科学主题的混合，以促进质量转化研究的发展。